Covid 19 Research using Clinical Trials (Home Page)
Maintenance or reduction of immunosuppressionWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
Correlated MeSH Terms (2)
There is one clinical trial.
Clinical Trials
This will be a randomized trial of maintenance versus reduction in immunosuppression in adult
patients (age >18 years old) with functioning renal transplants admitted to hospital with
confirmed COVID-19 disease.
NCT04420364 COVID Kidney Transplant; Complications Immunosuppression Other: Maintenance or reduction of immunosuppression
Primary Outcomes
Measure: Change in IL-6 concentration from baseline to day 7 Time: baseline to day 7
Secondary Outcomes
Measure: Change in IL-6 concentration from baseline to day 28 Time: Baseline to day 28
Measure: Change in T cell response to SARS-CoV-2 Time: Baseline to day 7 and day 28
Measure: Change in titer of serum anti-SARS-CoV-2 antibodies Time: Baseline to day 7 and day 28
Measure: Change in COVID-19 disease severity score (range 1 to 8; higher worse) Time: Through day 28
Measure: Proportion of patients needing non-invasive ventilation or intubation Time: Through day 28
Measure: Proportion of patients developing ANC < 500 cells per microliter Time: Through day 28
Measure: Proportion of patients developing lymphopenia < 400 cells per microliter Time: Through day 28
Measure: Length of hospital stay Time: Through day 28
Measure: Proportion of patients developing biopsy-proven acute rejection Time: Through day 28
Measure: In-hospital and 28-day mortality Time: Through day 28
Measure: Adverse and serious adverse events Time: Through day 28
No related HPO nodes (Using clinical trials)